HOME
WHO IS BDA
BDA DELIVERS
KEY PROJECTS
REFERENCE WORK 
PRINCIPALS & ASSOCIATES
CONTACT US 
Business Development Advisors
Reference Work

Hesed Biomed, an early stage private biotechnology company focused on developing technologies for treating cancer and immune disorders using antisense technology and catalytic antibody technology. Hesed had $4.5 M in NIH grant funding for its catalytic antibody research programs at MD Anderson Cancer Center. Had conducted a Phase I safety study for its p53 antisense oligonucleotide programs in leukemia. The company was sold to Abgenix in 2001. As part of the transaction the antisense technology was spun back to the Hesed shareholders including $1.75 M in start-up funding in a new company, Eleos. Eleos is commencing a phase II clinical study of its antisense p53 drug in leukemia patients at MD Anderson. The Eleos technology is protected by six US patents and their foreign counterparts.

How Sourced: Founder

Our involvement: Strategy, business plan, management, sale of business